PTGS2 and breast carcinoma: Our study's finding of an increased risk of breast cancer contrasts with findings from a hospital-based case–control study on selective COX-2 inhibitors (Harris et al, 2006), which demonstrated a significant risk reduction (OR 0.29, 95% CI 0.14–0.59) with daily use for at least 2 years.